期刊文献+

β-catenin、Smad4在胰腺癌发生中的作用 被引量:2

THE EXPRESSION OF β-CATENIN AND SMAD4 IN PANCREATIC CARCINOMA
原文传递
导出
摘要 目的探讨β-catenin、Smad4在胰腺癌发生、发展、转移、浸润过程中的作用。方法应用免疫组化方法检测β-catenin、Smad4在正常胰腺、胰腺癌组织中的表达。结果β-catenin在胰腺癌中的异常表达率为68.33%,明显高于正常组织(0),异常表达与年龄、性别、病理分化程度无关;与有无淋巴结转移、临床分期相关,有淋巴结转移的异常表达率明显高于无淋巴结转移,Ⅲ+Ⅳ期的异常表达率明显高于Ⅰ+Ⅱ期。Smad4在胰腺癌的阳性表达(33/60)明显低于正常组织(17/20),阳性表达与年龄、性别、病理分化程度、有无淋巴结转移、临床分期无相关性;在胰腺癌中β-catenin的异常表达与Smad4的阳性表达相关。结论β-catenin、Smad4共同参与了胰腺癌的发生,wnt/β-catenin通路和TGF-β/Smad通路可能存在交汇点。 Objective To investigate the abnormal expression of β- catenin and Smad4 in pancreatic carcinomas and its relationship with the biological behavior. Methods Immunohistochemistry was used to detect β - catenin and Smad4 in pancreatic carcinomas and normal pancreatic tissues. Results The abnormal rate olin- catenin expression in pancreatic carcinomas was 68.33% (41/ 60) ,higher than the rate of normal pancreatic tissues" expression (0.0%). The significant relationship was observed between β- catenin ex- pression and clinical stages and lymph node spread (P〈0; 05). Compared with the normal pancreatic tis- sues, the overexpression of Smad4 in pancreatic carcinomas was 55% (33/60). There was a significant difference(P〈0.05). No significant difference was found between the abnormal expression of β- catenin and Smad4 and the patients age, sex, tumor size and differentiation (P〉0.05). There was a significant re- lationship between the abnormal expression of β- catenin and Smad4. Conclusions β- catenin,Smad4 par- ticipate the tumorigenes of pancreatic cancer. There was signaling cross- talk between wnt/β- catenin and TGF - β/Smad pathways.
出处 《中国煤炭工业医学杂志》 2012年第6期791-793,共3页 Chinese Journal of Coal Industry Medicine
关键词 β—catenin SMAD4 免疫组化 胰腺癌 β-catenin Smad4 immunohistochemistry pancreatic carcinoma
  • 相关文献

参考文献14

二级参考文献312

  • 1王立夫,Sunil R.Hingorani,David A.Tuveson.内源性K-ras激活突变和Tp53失活突变共同作用产生干细胞胰腺癌[J].外科理论与实践,2005,10(3):236-240. 被引量:12
  • 2王旭东,战忠利.TGF-β及其受体与肿瘤的研究进展[J].中国肿瘤临床,2005,32(17):1016-1020. 被引量:28
  • 3唐卫中,高枫,李卫,唐宗江.结直肠癌APC、K-ras、p53基因突变检测[J].肿瘤,2006,26(3):282-284. 被引量:16
  • 4Qi-Ming Wang,Ye Zhang,Kai-Ming Yang,Hong-Ying Zhou,Hui-Jun Yang.Wnt/β-catenin signaling pathway is active in pancreatic development of rat embryo[J].World Journal of Gastroenterology,2006,12(16):2615-2619. 被引量:5
  • 5Wilkes MC, Mitchell H, Penheiter SG, et al. Transforming growth factor-{beta} activation ofphosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 2005; 65:10431- 10440.
  • 6Chow JY, Quach KT, Cabrera BL, Cabral JA, Beck SE, Carethers JM. RASPERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. Carcinogenesis 2007; 28:2321-2327.
  • 7Vogelmann R, Nguyen-Tat MD, Giehl K, Adler G, Wedlich D,Menke A. TGFbeta-induced downregulation of E-cadherin-based cell-cell adhesion depends on PI3-kinase and PTEN. J Cell Sci 2005; 118:4901-4912.
  • 8Valderrama-Carvajal H, Cocolakis E, Lacerte A, et al. Activin/ TGF-beta induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIE Nat Cell Biol 2002; 4:963-969.
  • 9He XC, Zhang J, Tong WG, et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-betacatenin signaling. Nat Genet 2004; 36:1117-1121.
  • 10Tian Q, He XC, Hood L, Li L. Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. Cell Cycle 2005; 4:215-216.

共引文献122

同被引文献14

  • 1程春生,董卫国,罗和生.Smad4蛋白在胃癌组织中的表达及其临床意义[J].临床内科杂志,2004,21(11):747-748. 被引量:2
  • 2Giardino A, Girelli R, Frigerio I, et al. Triple ap- proach strategy for patients with locally advanced pancreatic carcinoma [J]. HPB (Oxford), 2013, 15(8) :623 - 627.
  • 3Planchon SM, Waite KA, Eng C. The nuclear af- fairs of PTEN [J]. J Cell Sci, 2008,121(3): 249- 253.
  • 4Kasenda B, Bass A, Koeberle D, et al. Survival in overweight patients with advanced pancreatic carci- noma: a multicentre cohort study[J]. BMC Cancer, 2014,29(14) :728.
  • 5Janku F, Hong DS, Fu S, Assessing PIK3CA and PTEN in early- phase trials with PI3K/AKT/ roTOR inhibitors[J]. Cell Rep, 2014, 6(2):377- 387.
  • 6Schanzer JM, Wartha K, Croasdale R, et al. A no- vel glycoengineered bispecific antibody format for tar- geted inhibition of epidermal growth factor receptor (EGFR) and insulin- like growth factor receptor type Ⅰ (IGF- 1R) demonstrating unique molecular properties [J]. J Biol Chem, 2014,289(27) :18693 - 18706.
  • 7Ali S, Ahmad A, Aboukameel A, et al. Deregula- tion of miR - 146a expression in a mouse model of pancreatic cancer affecting EGFR signaling[J]. Cancer Lett, 2014,351 (1) :134 - 142.
  • 8Stock AM, Hahn SA, Troost G. Induction of pan- creatic cancer cell migration by an autocrine epideromal growth factor receptor activation [J]. Exp Cell Res, 2014,326(2) :307 - 314.
  • 9Jin X, Sun Y, Yang H, et al. Deregulation of the MiR - 193b - KRAS Axis Contributes to Impaired Cell Growth in Pancreatic Cancer [J]. PLoS One, 2015,10 (4) : e0125515.
  • 10Hong DS, Cabanillas ME, Wheler J, et al. Inhibi- tion of the Ras/Ra{/MEK/ERK and RET kinase pathways with the combination of the multikinase in- hibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid ma- lignancies[J]. J Clin Endocrinol Metab, 2011, 96 (4) :997 - 1005.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部